Filing Details

Accession Number:
0000947871-24-000583
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-07-02 16:54:31
Reporting Period:
2024-06-28
Accepted Time:
2024-07-02 16:54:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1561921 Tela Bio Inc. TELA () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Avenue
54Th Floor
New York NY 10022
No No Yes No
1502240 Orbimed Capital Gp Iv Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-06-28 378,000 $4.74 2,457,542 No 4 S Indirect See footnotes
Common Stock Disposition 2024-07-01 13,700 $4.68 2,443,842 No 4 S Indirect See footnotes
Common Stock Disposition 2024-07-02 36,600 $4.54 2,407,242 No 4 S Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
Footnotes
  1. These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP IV. By virtue of such relationships, OrbiMed Advisors and GP IV may be deemed to have voting power and investment power over the securities held by OPI IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI IV.
  2. Each of OrbiMed Advisors and GP IV disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.